Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

40.05 -0.06 (-0.16%)
Streaming Delayed Price Updated: 11:19 AM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020 
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Reports Third Quarter 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Fourth Quarter 2025 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
From Zenas BioPharma
Via GlobeNewswire
News headline image
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Reports Second Quarter 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Third Quarter 2025 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.